Impaired tissue factor pathway inhibitor function is associated with recurrent venous thromboembolism in patients with first unprovoked deep venous thrombosis

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 10, 2012, Pages 2208-2211

  Winckers, K ^a   Ten Cate Hoek, A J ^a,b   Beekers, K C M M ^a   Erkens, P ^a   Hamulyak K ^b   Ten Cate, H ^a   Hackeng, T M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; IDRAPARINUX; ORAL CONTRACEPTIVE AGENT; PROTEIN S; RIVAROXABAN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULANT THERAPY; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; ECHOGRAPHY; ENZYME ACTIVITY; FOLLOW UP; HUMAN; IN VIVO STUDY; LETTER; LUNG EMBOLISM; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECURRENT DISEASE; SIGNAL TRANSDUCTION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THROMBIN TIME; VENOUS THROMBOEMBOLISM;

AGED; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN S; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; THROMBIN; TIME FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84866849565     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04884.x     Document Type: Letter

References (13)

1. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004; 1: 439-56.
2. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
3. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 2006; 103: 3106-11.
4. Sere KM, Rosing J, Hackeng TM. Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance. Blood 2004; 104: 3624-30.
5. ten Cate-Hoek AJ, Dielis AW, Spronk HM, van Oerle R, Hamulyak K, Prins MH, ten Cate H. Thrombin generation in patients after acute deep-vein thrombosis. Thromb Haemost 2008; 100: 240-5.
6. Maurissen LF, Castoldi E, Simioni P, Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010; 8: 750-8.
7. Hackeng TM, Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 2009; 29: 2015-20.
8. Baglin T. Using the laboratory to predict recurrent venous thrombosis. Int J Lab Hematol 2011; 33: 333-42.
9. Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012; 32: 563-8.
10. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-8.
11. Hoke M, Kyrle PA, Minar E, Bialonzcyk C, Hirschl M, Schneider B, Kollars M, Weltermann A, Eichinger S. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005; 94: 787-90.
12. Zakai NA, Lutsey PL, Folsom AR, Heckbert SR, Cushman M. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology. Thromb Haemost 2010; 104: 207-12.
13. ten Cate H. Thrombin generation in clinical conditions. Thromb Res 2012; 129: 367-70.